AKT activation is a feature of CALR mutant myeloproliferative neoplasms

被引：3

作者：

Fu, Chunling ^{[1
,2
]}

Wen, Qiang Jeremy ^{[2
]}

Marinaccio, Christian ^{[2
]}

Ling, Te ^{[2
]}

Chen, Wei ^{[1
,2
]}

Bulic, Marinka ^{[2
]}

Lasho, Terra ^{[3
]}

Tefferi, Ayalew ^{[3
]}

Crispino, John D. ^{[2
]}

Xu, Kailin ^{[1
]}

机构：

[1] Xuzhou Med Univ, Blood Dis Inst, Xuzhou, Jiangsu, Peoples R China

[2] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA

[3] Mayo Clin, Div Hematol Oncol, Rochester, MN USA

来源：

LEUKEMIA | 2019年 / 33卷 / 01期

关键词：

THROMBOPOIETIN RECEPTOR; CALRETICULIN; INDUCE;

D O I：

10.1038/s41375-018-0224-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：271 / 274

页数：4

共 9 条

[1] Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants [J].

Chachoua, Ilyas ;

Pecquet, Christian ;

El-Khoury, Mira ;

Nivarthi, Harini ;

Albu, Roxana-Irina ;

Marty, Caroline ;

Gryshkova, Vitalina ;

Defour, Jean-Philippe ;

Vertenoeil, Gaelle ;

Ngo, Anna ;

Koay, Ann ;

Raslova, Hana ;

Courtoy, Pierre J. ;

Choong, Meng Ling ;

Plo, Isabelle ;

Vainchenker, William ;

Kralovics, Robert ;

Constantinescu, Stefan N. .

BLOOD, 2016, 127 (10) :1325-1335

[2] Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation [J].

Elf, Shannon ;

Abdelfattah, Nouran S. ;

Chen, Edwin ;

Perales-Paton, Javier ;

Rosen, Emily A. ;

Ko, Amy ;

Peisker, Fabian ;

Florescu, Natalie ;

Giannini, Silvia ;

Wolach, Ofir ;

Morgan, Elizabeth A. ;

Tothova, Zuzana ;

Losman, Julie-Aurore ;

Schneider, Rebekka K. ;

Al-Shahrour, Fatima ;

Mullally, Ann .

CANCER DISCOVERY, 2016, 6 (04) :368-381

[3] Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion [J].

Han, Lijuan ;

Schubert, Claudia ;

Koehler, Johanna ;

Schemionek, Mirle ;

Isfort, Susanne ;

Bruemmendorf, Tim H. ;

Koschmieder, Steffen ;

Chatain, Nicolas .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[4] The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [J].

Hobbs, Gabriela S. ;

Rozelle, Sarah ;

Mullally, Ann .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) :613-+

[5] AKT is a therapeutic target in myeloproliferative neoplasms [J].

Khan, I. ;

Huang, Z. ;

Wen, Q. ;

Stankiewicz, M. J. ;

Gilles, L. ;

Goldenson, B. ;

Schultz, R. ;

Diebold, L. ;

Gurbuxani, S. ;

Finke, C. M. ;

Lasho, T. L. ;

Koppikar, P. ;

Pardanani, A. ;

Stein, B. ;

Altman, J. K. ;

Levine, R. L. ;

Tefferi, A. ;

Crispino, J. D. .

LEUKEMIA, 2013, 27 (09) :1882-1890

[6] A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation [J].

Kollmann, K. ;

Warsch, W. ;

Gonzalez-Arias, C. ;

Nice, F. L. ;

Avezov, E. ;

Milburn, J. ;

Li, J. ;

Dimitropoulou, D. ;

Biddie, S. ;

Wang, M. ;

Poynton, E. ;

Colzani, M. ;

Tijssen, M. R. ;

Anand, S. ;

McDermott, U. ;

Huntly, B. ;

Green, T. .

LEUKEMIA, 2017, 31 (04) :934-944

[7] Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis [J].

Marty, Caroline ;

Pecquet, Christian ;

Nivarthi, Harini ;

El-Khoury, Mira ;

Chachoua, Ilyas ;

Tulliez, Micheline ;

Villeval, Jean-Luc ;

Raslova, Hana ;

Kralovics, Robert ;

Constantinescu, Stefan N. ;

Plo, Isabelle ;

Vainchenker, William .

BLOOD, 2016, 127 (10) :1317-1324

[8] Definition and management of ruxolitinib treatment failure in myelofibrosis [J].

Pardanani, A. ;

Tefferi, A. .

BLOOD CANCER JOURNAL, 2014, 4 :e268-e268

[9] Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib [J].

Shide, K. ;

Kameda, T. ;

Yamaji, T. ;

Sekine, M. ;

Inada, N. ;

Kamiunten, A. ;

Akizuki, K. ;

Nakamura, K. ;

Hidaka, T. ;

Kubuki, Y. ;

Shimoda, H. ;

Kitanaka, A. ;

Honda, A. ;

Sawaguchi, A. ;

Abe, H. ;

Miike, T. ;

Iwakiri, H. ;

Tahara, Y. ;

Sueta, M. ;

Hasuike, S. ;

Yamamoto, S. ;

Nagata, K. ;

Shimoda, K. .

LEUKEMIA, 2017, 31 (05) :1136-1144

← 1 →